|
n |
PI of hormone receptor status |
PI of HER-2 status |
PI of various factors (multivariate) |
Claude et al., 2005 |
120 |
none |
no data |
performance status, lymphopenia |
Bartsch et al., 2006 |
174 |
none |
none |
performance status, number of metast. sites |
Le Scodan et al., 2007 |
117 |
receptor negative sign. worse |
none |
performance status, lymphopenia, hormone receptor status |
Nam et al., 2008 |
126 |
receptor negative sign. worse |
HER-2 negative sign. worse |
number of metast. sites, age, hormone and HER-2 receptor status, leptomeningeal disease |
Eichler et al., 2008 |
83 |
none |
HER-2 negative sign. worse |
HER-2 receptor status, number of brain metast., local disease control |
Melisko et al., 2008 |
112 |
receptor negative sign. worse |
none |
hormone receptor status, age, performance status, stable or responding systemic disease |
Harputluoglu et al., 2008 |
144 |
none |
none |
number of brain metast. |
Park et al., 2009 |
125 |
none |
HER-2 positive sign. worse |
HER-2 receptor status, performance status |
Altundag et al., 2007 |
420 |
receptor negative sign. worse |
none |
age, hormone receptor status |
Niwinska et al., 2009 |
222 |
best prognosis in luminal breast cancer |
worst prognosis in triple-negative breast cancer |
RPA class, biological subtype |
Viani et al., 2007 |
174 |
no data |
no data |
extracranial metastases, RPA class |
Mahmoud-Ahmed et al., 2002 |
116 |
no data |
no data |
performance status |
Present study |
90 |
none |
worst prognosis in triple-negative breast cancer |
performance status, age, interval |
